

1

Supplementary Information

2 **Targeted delivery and ROS-responsive release of celastrol by**
3 **macrophage membrane biomimetic liposome alleviates acute kidney**
4 **injury**

5

6 Guangqin Cheng^{a,&}, Dongxu Bai^{a,&}, Weiyi Chen^{a,&}, Junmei Wang^a, Jian Xu^a,
7 Yongping Zhang^a, Lin Li^d, Qing Lin^d, Zhirong Zhang^d, Jinghua Ruan^{c,*}, Ling
8 Zhang^{b,*}, Ling Guo^{a,*}

9

10 ^aNational Engineering Technology Research Center for Miao Medicine, Guizhou Engi
11 neering Technology Research Center for Processing and Preparation of Traditional Ch
12 inese Medicine and Ethnic Medicine, College of Pharmaceutical Sciences, Guizhou U
13 niversity of Traditional Chinese Medicine, Guiyang, 550025, P. R. China.

14

15 ^bCollege of Polymer Science and Engineering, West China School of Public Health,
16 Med-X center of materials, Sichuan University, Chengdu, 610065, P. R. China.

17

18 ^cThe First Affiliated Hospital, Guizhou University of Traditional Chinese Medicine,
19 Guiyang 550001, P. R. China.

20

21 ^dWest China School of Pharmacy, Key Laboratory of Drug-Targeting and Drug
22 Delivery System of the Education Ministry, Sichuan Engineering Laboratory for
23 Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial
24 Technology, Sichuan University, Chengdu, 610041, P. R. China.

25

26

27

28 &These authors contributed equally: Guangqin Cheng, Dongxu Bai, Weiyi Chen


29

30 *Corresponding authors. E-mail address: RJH7737@163.com (Jinghua Ruan);
31 zhangling83@scu.edu.cn (Ling Zhang); guoling032@gzy.edu.cn (Ling Guo).

32


33 Supplemental Figures.

34




35

36 **Figure S1. Characterization of MM and CLT formulations.** (A-E) Zeta potential
37 of PT, ST, MPT, MST, and MM measured by dynamic light scattering. (F) Particle
38 size and size distribution of MM measured by dynamic light scattering. Data are
39 mean \pm S.D. (n = 3).




40

41 **Figure S2. The serum stability of CLT formulations.** (A-C) The variations in
 42 particle size, zeta potential, and PDI of PT, ST, MPT or MST after incubation with an
 43 equal volume (v/v) of FBS for 72 h. Data are mean \pm S.D. (n = 3).




44

45 **Figure S3.** *In vitro* release profile of ST were evaluated in the presence of 0, 2, and 5
46 μM H₂O₂. Data are mean ± S.D. (n = 3).




47

48 **Figure S4. *In vivo* biodistribution of MSR in unilateral IRI mice.** (A-C) The
 49 biodistribution and quantification of MSR accumulated in major organs were assessed
 50 at 1, 3, 6, and 24 h following intravenous administration. Data are mean \pm S.D. (n = 3).
 51 * P < 0.05, ** P < 0.01, *** P < 0.001. Statistical significance was determined by
 52 one-way ANOVA with Tukey *post hoc* test.



54

55 **Figure S5. The cytotoxicity of CLT formulations on HK-2 cells.** The HK-2 cell
56 viability after incubating with various concentration of CLT, PT, ST, MPT, or MST
57 for 24 h evaluated using the CCK-8 assay. Data are mean \pm S.D. (n = 5).




58

59 **Figure S6. *In vitro* cytoprotective activities of PB, SB, MPB, and MSB.** (A) The
 60 HK-2 cell viability after incubating with PB, SB, MPB, and MSB for 24 h evaluated
 61 using the CCK-8 assay (n = 5). (B) Cell viability of H/R treated HK-2 cells incubated
 62 with blank formulations (n = 5). (C) CLSM images and the semi-quantitative analysis
 63 of live and dead cells in H/R treated HK-2 cells stained with Calcein-AM/PI
 64 following various treatments (n = 3). Scale bar = 100 μ m. (D) CLSM images and the
 65 semi-quantitative analysis of mitochondrial membrane potential in H/R treated HK-2
 66 cells stained with JC-1 following various treatments (n = 3). Scale bar = 100 μ m. Data
 67 are mean \pm S.D., compared to the model group, **** P < 0.0001. ns, not significant.
 68 Statistical significance was determined by one-way ANOVA with Tukey *post hoc* test.


69

70



71
 72 **Figure S7. In vitro anti-oxidant and anti-inflammatory activities of PB, SB, MPB,**
 73 **and MSB.** (A) CLSM images of intracellular ROS in H/R treated HK-2 cells
 74 following various treatments. Scale bar = 100 μm. (B) quantitative results and (C)
 75 FACS analysis of ROS level in H/R treated HK-2 cells following various treatments
 76 (n = 3). (D) Representative images of migrated THP-1 macrophages subjected to
 77 various CM. (E) Semi-quantitative analysis of macrophage migration (n = 3). Data are
 78 mean ± S.D., compared to the model group, * P < 0.05, ** P < 0.01, *** P < 0.001. ns,
 79 not significant. Statistical significance was determined by one-way ANOVA with
 80 Tukey *post hoc* test.

81
 82
 83
 84
 85
 86
 87
 88



89

90 **Figure S8. Evaluation of the anti-inflammatory effect of MST *in vitro*.** (A)

91 Schematic illustration of the experimental procedure for collecting CM and

92 conducting the Transwell migration assay. (B) Representative images of migrated


93 THP-1 macrophages subjected to various CM. (C) Semi-quantitative analysis of

94 macrophage migration. Data are mean \pm S.D. (n = 3). Compared to the model-CM

95 group, * P < 0.05, ** P < 0.01, *** P < 0.001. ns, not significant. Statistical

96 significance was determined by one-way ANOVA with Tukey *post hoc* test.

97



100 **Figure S9. The biosafety evaluation of CLT formulations.** (A) The changes in the
 101 organ index of following intravenous administration of saline, CLT, PT, ST, MPT or
 102 MST. (B–F) WBC, PLT, RBC, HCT and HGB levels in blood of rats following
 103 intravenous administration of saline, CLT, PT, ST, MPT or MST. Data are mean \pm
 104 S.D. (n = 6). ns, not significant. Statistical significance was determined by one-way
 105 ANOVA with Tukey *post hoc* test.